Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Schizophrenia · Narcolepsy Type 1

Alkermes Pharma Ireland

Alkermes Pharma Ireland patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Dublin, USA HQ
27 Employees
EMA registrant Type
Company details
Status
Public
HQ
Dublin, USA
Employees
27
Programs
6
Drugs
3
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Alkermes Pharma Ireland patents

25 pharmaceutical patents indexed for Alkermes Pharma Ireland. 0 expire within 24 months.

Alkermes Pharma Ireland has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

25 patents

Patent portfolio

  1. AU 2022263543

    Pharmaceutical compositions comprising sorbitan esters

    Expires Wed May 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 2023302008

    METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE

    Expires Wed Sep 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2023156493

    FORMES CRISTALLINES DE NALTREXONE

    Expires Wed Aug 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2023154894

    COMPOSITIONS ET PROCÉDÉS D'IMMUNOTHÉRAPIE ANTICANCÉREUSE

    Expires Wed Aug 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. CY 2022006

    ΠΡΟΦΑΡΜΑΚΑ ΦΟΥΜΑΡΙΚΩΝ ΑΛΑΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΑΓΩΓΗ ΠΟΙΚΙΛΩΝ ΝΟΣΩΝ

    Expires Wed Dec 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 2022354866

    IMMEDIATE RELEASE MULTILAYER TABLET

    Expires Wed Nov 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 3172874

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    Expires Wed Nov 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. CA 3172871

    COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION

    Expires Wed Nov 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. CA 3175580

    AGENTS IMMUNOSTIMULATEURS EN COMBINAISON AVEC DES INHIBITEURS DE L'ANGIOGENESE

    Expires Wed Oct 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CA 3175356

    AGENTS IMMUNOSTIMULATEURS EN COMBINAISON AVEC DES INHIBITEURS DE L'ANGIOGENESE

    Expires Wed Oct 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 2021163596

    IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS

    Expires Wed May 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 2021038684

    Compositions and Methods for Cancer Immunotherapy

    Expires Wed Feb 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2020094634

    PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS

    Expires Wed May 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 2020016151

    NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS

    Expires Wed Jan 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 2020017529

    NOVEL THIENOTHIOPHENE COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS

    Expires Wed Jan 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 2019298716

    Aripiprazole Dosing Strategy

    Expires Wed Sep 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. HR P20190642

    ARIPIPRAZOLE PRODRUG COMPOSITIONS

    Expires Thu May 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 2017231981

    COMPOSITIONS OF MULTIPLE ARIPIPRAZOLE PRODRUGS

    Expires Wed Aug 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. EP 3182958

    ARIPIPRAZOL-PRODRUGZUSAMMENSETZUNG

    Expires Tue Jun 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 2017136004

    Opioid Agonist Antagonist Combinations

    Expires Wed May 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 2016228376

    MONOMETHYLFUMARATE PRODRUG COMPOSITIONS

    Expires Wed Aug 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 2016051546

    CRYSTALLIZATION PROCESS OF ARIPIPRAZOLE DERIVATIVES IN EXTENDED RELEASE FORMULATIONS FOR TREATMENT OF SCHIZOPHRENIA

    Expires Wed Feb 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 2016045495

    ARIPIPRAZOLE PRODRUG COMPOSITIONS

    Expires Wed Feb 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 2015265529

    ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS

    Expires Wed Sep 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9132096

    Abuse resistant pharmaceutical compositions

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Alkermes Pharma Ireland have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Alkermes Pharma Ireland patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.